Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi Shaun,
wrt q16 / q32 subcontract manufacture.
It may be the case that a large increase in output is required, which means current facility is too small.
That would make the decision to outsource easier.
Address is 1 Wainstones Court Stokesley Business Park, Stokesley, Middlesborough, TS9 5JY.
I plugged the post code into google maps, and I think what comes up is inadequate, - what do you think?
Done the same for the Dublin Address: IT-IS Life Science Ltd
148, Richmond Road, Dublin 3 DO3W2H1
Was directed to a map with link below:
https://www.google.co.uk/maps/place/148+Richmond+Rd,+Fionnradharc,+Baile+%C3%81tha+Cliath+3,+D03+W2H1,+Ireland/@53.3654473,-6.2494273,335m/data=!3m2!1e3!4b1!4m5!3m4!1s0x48670e66515ba52b:0xe7aed634c22f268d!8m2!3d53.3654473!4d-6.2487766
Still nowhere near big enough, and does not confirm IT-IS live there.
This leads me to think that the manufacturing is already sub-contracted.
What are your thoughts on this?
Hillseeker, - They are providing support to foreign purchasers of instruments now, and one of the benefits of q16 / q32 use with Primerdesign assay is that the whole process is quick and simple.
I know we are planning to make it simpler yet, so I'm confident that computer based training and use of Zoom etc can successfully train those hospital staff who have never set foot in a laboratory, and I take your point about the new assay under development.
Buy Too High, I agree with you entirely regarding the scaling up of manufacturing. They have put a multimillion pound (I think it was £1.9m) incentive to the current management with regard to an increase in output of these two Q devices.
But what I was saying to Bramley was that we cannot simply ship these abroad to other hospitals. They need sales support to ensure they are fully utilised. This is being set up in UK but it will be more difficult to expand this service quickly to other countries. The solution, however, may come in terms of the new easier to use PCR tests currently under development that will be used in these machines. They will not require a trained technician to pre-process them before putting them into the machines. So the dots will be joined, the new product (easy to use test) will come and we can then look at shipping Q16 and Q32 overseas and to other non-hospital establishment (e.g. care homes) in the UK
Hillseeker re your 17:07 post
"My only reservation about international sales is this: In the UK, Novacyt are building an army of reps/specialist who are able to go into hospitals and support. I assume they will at first train the hospital personnel and then periodically visit to ensure the machines are being used effectively. They will, in time, then look at using these visits to explain other tests that can be used on the machines and expand their repertoire of sales to a more sustainable model that will set the company up well into the future."
++++
wrt International sales:
IMO one of the reasons IT-IS has been bought is because it's production output of q16 / q32 instruments was not likely to meet the number of orders GM was needing to place.
My feeling is the UK authorities wanted to order 1000 instruments, but had to settle for a 2 stage delivery deal.
To furnish the 300 now / 700 later order, I'm guessing worst case that GM may have had to redirect or defer some instrument deliveries destined for foreign buyers.
If that has happened, that would not be good business, but buying the company to urgently invest in more efficient production facilities, - (and incentivising the previous directors to do this) - is the next best thing, and secures the supply chain by stopping competitors buying IT-IS.
If we keep looking for job adverts for IT-IS / Primerdesign / Novacyt production staff in Middlesborough, (or perhaps Dublin), we will expect an increase in number of instruments shortly.
The past directors will be best placed to know how to achieve increased output, as they will have been looking at this problem for a while.
Another way of increasing output is to contract a manufacturer, in the same way that Assay production has been contracted out, but you don't need to incentivise past directors if that is to happen.
I just feel current output is nowhere near satisfactory for GM's needs, and it will be international sales that will be hit until production ramps up.
Currently, Mullis and Dyer are still the only 2 named directors of IT-IS on Companies House website.
Bramley, Sir -I think you are spot on. With regard to the application and potential market of these machines the possibilities are endless and, especially in the case of hospitals, will be enduring.
My only reservation about international sales is this: In the UK, Novacyt are building an army of reps/specialist who are able to go into hospitals and support. I assume they will at first train the hospital personnel and then periodically visit to ensure the machines are being used effectively. They will, in time, then look at using these visits to explain other tests that can be used on the machines and expand their repertoire of sales to a more sustainable model that will set the company up well into the future.
So my reservation is that it will not be so easy to scale this support at an international level. Nor will it be so easy to use in establishments that are not equipped with the correct facilities or trained ancillary staff. This may be the reason why we have not heard anything on the care home front. The solution is the new simpler to use product and this is taking time to develop.
I suspect the wider roll-out will be dependent on this new product. So for those who are in early and happy to wait...
Effing hope so!
Shorters going to get burnt again very soon when news breaks :)
Just talking to a friend about this and the new test for the q16 and q32 machines. Let’s not forget this is a global company and it’s not just about the uk. Think about this for a second. The Uk has about 1100 hospitals which we are signed up for 300. Hopefully we will get the jan contract for the other 700. France has 1400 hospitals, Germany has 2200 hospitals. Each hospitals takes several q16 or q32 machines. We are then supporting these with tests at roughly $10 profit per test. Suddenly this isn’t just about the UK or France. We could equally land a massive order from anywhere in the world. Just imagine if Trump wanted these in every USA hospital.
This imho is going to explode very soon. More information today on how antibodies don’t stay in the body so any vaccine just is viable for a couple of months. The only way we are going to cope with this going forward is going to be through testing.
Regards
Bramley1967